Philip Marshall
CEO of ORIL
Join Date
June 2018
Country
Gender
Male
Age
Not Specified
About Philip Marshall
Over 30 years experience in senior executive roles in pharma & biotech companies;
Founder & Director of global specialist consultancy firm to pharma;
Authorised Australia Govt. GMP Auditor;
Co-investor of ORIL’s chemistry patents
Founder & Director of global specialist consultancy firm to pharma;
Authorised Australia Govt. GMP Auditor;
Co-investor of ORIL’s chemistry patents
Companies & Work
Oncology Research International Ltd
ORIL is a public-unlisted biotech start-up headquartered in Adelaide, Australia;
Founded by a cancer survivor, it has been carrying on the research work in low-cost & effective treatment of cancer based on chemical compounds found in natural recurring substance, using traditional Chinese medicine (TCM) approach;
Currently the Company’s new chemical entity ORIL19 has been approved strong efficacy in curing liver & breasts cancer during pre-clinical research; the Company has been strongly encouraged & approved by US FDA to conduct clinical phase 1 research, but is in need of approx. AU$2-5m (US$1.5m) for funding the regulatory filing costs & ongoing research expenses
Founded by a cancer survivor, it has been carrying on the research work in low-cost & effective treatment of cancer based on chemical compounds found in natural recurring substance, using traditional Chinese medicine (TCM) approach;
Currently the Company’s new chemical entity ORIL19 has been approved strong efficacy in curing liver & breasts cancer during pre-clinical research; the Company has been strongly encouraged & approved by US FDA to conduct clinical phase 1 research, but is in need of approx. AU$2-5m (US$1.5m) for funding the regulatory filing costs & ongoing research expenses
